Literature DB >> 15105267

The relevance of iron in the pathogenesis of Parkinson's disease.

Mario E Götz1, Kay Double, Manfred Gerlach, Moussa B H Youdim, Peter Riederer.   

Abstract

Investigations that revealed increased levels of iron in postmortem brains from patients with Parkinson's disease (PD) as compared to those from individuals not suffering from neurological disorders are reported. The chemical natures in which iron predominates in the brain and the relevance of neuromelanin for neuronal iron binding are discussed. Major findings have been that iron levels increase with the severity of neuropathological changes in PD, presumably due to increased transport through the blood-brain barrier in late stages of parkinsonism. Glial iron is mainly stored as ferric iron in ferritin, while neuronal iron is predominantly bound to neuromelanin. Iron overload may induce progressive degeneration of nigrostriatal neurons by facilitating the formation of reactive biological intermediates, including reactive oxygen species, and the formation of cytotoxic protein aggregates. There are indications that iron-mediated neuronal death in PD proceeds retrogradely. These results are also discussed with respect to their relevance for disease progression in relation to cytotoxic alpha-synuclein protofibril formation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105267     DOI: 10.1196/annals.1306.017

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  88 in total

1.  Two different binding modes of α-synuclein to lipid vesicles depending on its aggregation state.

Authors:  Tobias Högen; Johannes Levin; Felix Schmidt; Mario Caruana; Neville Vassallo; Hans Kretzschmar; Kai Bötzel; Frits Kamp; Armin Giese
Journal:  Biophys J       Date:  2012-04-03       Impact factor: 4.033

Review 2.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 3.  Effects of opiates and HIV proteins on neurons: the role of ferritin heavy chain and a potential for synergism.

Authors:  Lindsay Festa; Olimpia Meucci
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

Review 4.  Pathogenic implications of iron accumulation in multiple sclerosis.

Authors:  Rachel Williams; Cassandra L Buchheit; Nancy E J Berman; Steven M LeVine
Journal:  J Neurochem       Date:  2011-11-11       Impact factor: 5.372

Review 5.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

6.  Distribution of ferritin in the rat hippocampus after kainate-induced neuronal injury.

Authors:  En Huang; Wei-Yi Ong
Journal:  Exp Brain Res       Date:  2004-11-20       Impact factor: 1.972

7.  Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.

Authors:  Guangwei Du; Mechelle M Lewis; Christopher Sica; Lu He; James R Connor; Lan Kong; Richard B Mailman; Xuemei Huang
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

8.  Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Christopher Gatenby; Sally Friend; Kenneth R Maravilla; Shu-Ching Hu; Kevin C Cain; Pinky Agarwal; Yoshimi Anzai
Journal:  J Neurol Sci       Date:  2017-04-23       Impact factor: 3.181

9.  GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein.

Authors:  Clemens R Scherzer; Jeffrey A Grass; Zhixiang Liao; Imelda Pepivani; Bin Zheng; Aron C Eklund; Paul A Ney; Juliana Ng; Meghan McGoldrick; Brit Mollenhauer; Emery H Bresnick; Michael G Schlossmacher
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-31       Impact factor: 11.205

Review 10.  Modulation of alpha-synuclein aggregation by dopamine: a review.

Authors:  Su Ling Leong; Roberto Cappai; Kevin Jeffrey Barnham; Chi Le Lan Pham
Journal:  Neurochem Res       Date:  2009-05-15       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.